Table 1
Basal clinicopathological characteristics of 246 HCC patients with PVTT with and without PA-TACE
| Features | Recurrence more than one month (n=246) | |||
|---|---|---|---|---|
| Total patients (n=246) | Non-PA-TACE (n=156) | PA-TACE (n=90) | P | |
| Preoperative Factors | ||||
| Age (mean (SD)) | 48.62 (10.43) | 47.88 (10.27) | 49.89 (10.62) | 0.147 |
| Sex (Male/Female) (%) | 226 (91.9)/20 (8.1) | 140 (89.7)/16 (10.3) | 86 (95.6)/4 (4.4) | 0.172 |
| Tumor rupture (Yes/No) (%) | 8 (3.3)/238 (96.7) | 6 (3.8)/150 (96.2) | 2 (2.2)/88 (97.8) | 0.750 |
| Child-pugh (A/B) (%) | 209 (85.0)/37 (15.0) | 141 (90.4)/15 (9.6) | 68 (75.6)/22 (24.4) | 0.003 |
| HBsAg (Positive/Negative) (%) | 222 (90.2)/24 (9.8) | 144 (92.3)/12 (7.7) | 78 (86.7)/12 (13.3) | 0.225 |
| HBV-DNA (≥2000/<2000 IU/mL) (%) | 128 (52.0)/118 (48.0) | 84 (53.8)/72 (46.2) | 44 (48.9)/46 (51.1) | 0.537 |
| Antiviral therapy (Yes/No) (%) | 18 (7.3) /228 (92.7) | 9 (5.8) /147 (94.2) | 9 (10.0) /81 (90.0) | 0.330 |
| AFP (˃400/≤400, ng/ml) (%) | 167 (67.9)/79 (32.1) | 110 (70.5)/46 (29.5) | 57 (63.3)/33 (36.7) | 0.308 |
| Tbi (mean, μmol/L) (SD) | 16.72 (24.89) | 18.51 (30.89) | 13.61 (5.24) | 0.138 |
| PALB (mean, g/L) (SD) | 178.88 (56.10) | 184.29 (60.89) | 169.51 (45.46) | 0.046 |
| Alb (mean, g/L) (SD) | 41.28 (3.75) | 41.22 (3.88) | 41.41 (3.54) | 0.703 |
| PLT (≥100/<100*109) (%) | 29 (11.8)/217 (88.2) | 24 (15.4)/132 (84.6) | 5 (5.6)/85 (94.4) | 0.036 |
| INR (mean (SD)) | 1.01 (0.08) | 1.01 (0.08) | 1.00 (0.07) | 0.482 |
| Intraoperative and Pathological Factors | ||||
| Transfusion (Yes/No) (%) | 92 (37.4)/154 (62.6) | 71 (45.5)/85 (54.5) | 21 (23.3)/69 (76.7) | 0.001 |
| Type of resection (anatomical/nonanatomical) (%) | 75 (30.5)/171 (69.5) | 45 (28.8)/111 (71.2) | 30 (33.3)/60 (66.7) | 0.553 |
| Hilar clamping time (mean, minutes) (SD) | 20.64 (11.98) | 20.43 (13.27) | 21.00 (9.41) | 0.72 |
| Tumor size (<10/5-10/≤5cm) (%) | 92 (37.4)/111 (45.1)/43 (17.5) | 67 (42.9)/67 (42.9)/22 (14.1) | 25 (27.8)/44 (48.9)/21 (23.3) | 0.034 |
| Tumor Number (>1/1) (%) | 86 (35.0)/160 (65.0) | 55 (35.3)/101 (64.7) | 31 (34.4)/59 (65.6) | 1.000 |
| Cirrhosis (Yes/No) (%) | 153 (62.2)/93 (37.8) | 103 (66.0)/53 (34.0) | 50 (55.6)/40 (44.4) | 0.135 |
| Tumor capsule (Complete/Incomplete/Absent) (%) | 13 (5.3)/112 (45.5)/121 (49.2) | 9 (5.8))/62 (39.7)/85 (54.5 | 4 (4.4)/50 (55.6)/36 (40.0) | 0.056 |
| Satellite lesions (Yes/No) (%) | 32 (13.0)/214 (87.0) | 21 (13.5)/135 (86.5) | 11 (12.2)/79 (87.8) | 0.935 |
| MVI (Yes/No) (%) | 216 (87.8)/30 (12.2) | 142 (91.0)/14 (9.0) | 74 (82.2)/16 (17.8) | 0.067 |
| Edmondson-Steiner grade (III-IV/II) (%) | 33 (13.4)/213 (86.6) | 11 (7.1)/145 (92.9) | 22 (24.4)/68 (75.6) | <0.001 |
| Postoperative and prePA-TACE | ||||
| postHBsAg (Positive/Negative) (%) | 222 (90.2)/24 (9.8) | 144 (92.3)/12 (7.7) | 78 (86.7)/12 (12.3) | 0.225 |
| postHBV-DNA (≥2000/<2000 IU/mL) (%) | 101 (41.1)/145 (58.9) | 71 (45.5)/85 (54.5) | 30 (34.4)/60 (65.6) | 0.083 |
| postAFP (>400/≤400, ng/ml) (%) | 93 (37.8)/153 (62.2) | 75 (48.1)/81 (51.9) | 18 (20.0)/72 (80.0) | <0.001 |
| postTbi (mean (SD)) | 21.31 (38.82) | 25.18 (48.18) | 14.59 (5.82) | 0.039 |
| postAlb (mean (SD)) | 43.53 (35.09) | 40.66 (23.67) | 48.52 (48.73) | 0.091 |
| postPLT (≥100/<100×109) (%) | 38 (15.4)/208 (84.6) | 25 (16.0)/131 (84.0) | 13 (14.4)/77 (85.6) | 0.883 |
| postINR (mean (SD)) | 1.08 (0.10) | 1.08 (0.11) | 1.07 (0.09) | 0.268 |
| postAntiviral therapy (Yes/No) (%) | 25 (10.2)/221 (89.8) | 13 (8.3)/143 (91.7) | 12 (13.3)/78 (86.7) | 0.302 |
Bold values indicate statistical significance (P < 0.05). HCC, hepatocellular carcinoma; PVTT, Portal Vein Tumor Thrombus; PA-TACE, postoperative adjuvant transarterial chemoembolization; AFP, α-fetoprotein; Tbi, total bilirubin; PALB, prealbumin; Alb, albumin; PLT, blood platelet; INR, international normalized ratio; MVI, microvascular invasion.